(Q44659889)

5 December 2017

title

Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect (English)

1 reference

5 December 2017

Nefazodone Inhibits Methylprednisolone Disposition and Enhances its Adrenal-Suppressant Effect (English)

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

3 April 2024

1 reference

cytochrome P-450 enzyme inhibitors

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624194

3 April 2024

author name string

Michael Kotlyar

1

1 reference

5 December 2017

Michael Golding

3

1 reference

5 December 2017

Edwin R. Brewer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624194

3 April 2024

Stanley W. Carson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14624194

3 April 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

full work available at URL

5 December 2017

https://journals.lww.com/10.1097/01.jcp.0000095343.32154.1d

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Journal of Clinical Psychopharmacology

3 April 2024

published in

1 reference

5 December 2017

volume

23

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

652-656

1 reference

Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.

5 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Apparent interaction between nefazodone and cyclosporine

3 April 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Interactions between cyclosporine and newer antidepressant medications

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Nefazodone and cyclosporine drug-drug interaction

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Simultaneous analysis of methylprednisolone hemisuccinate, cortisol and methylprednisolone by normal-phase high-performance liquid chromatography in human plasma

3 April 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine

3 April 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam

3 April 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Nefazodone-induced carbamazepine toxicity

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion

3 April 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol

3 April 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

The effect of troleandomycin on methylprednisolone elimination

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone

3 April 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects

3 April 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Gender effects in pharmacokinetics and pharmacodynamics

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

3 April 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.JCP.0000095343.32154.1D

3 April 2024

Identifiers

1 reference

5 December 2017

1 reference